Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Clinical trial NCT02981303 · COMPLETED
Trial details
- NCT number
- NCT02981303
- Sponsor
- HiberCell, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-22
- Primary completion
- 2020-12-31
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.